From Bench to Bedside: Herausforderungen in der Entwicklung von gentherapeutischen Ansätzen

Klin Monbl Augenheilkd 2022; 239(03): 261-262
DOI: 10.1055/a-1739-3825

Editorial

From Bench to Bedside: Challenges in the Development of Genetherapeutic Approaches

Claudia Priglinger

,

M. Dominik Fischer

Literatur
1 Quinn J, Musa A, Kantor A. et al. Genome-Editing Strategies for Treating Human Retinal Degenerations. Hum Gene Ther 2021; 32: 247-259
2 Gange WS, Sisk RA, Besirli CG. et al. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis. Ophthalmol Retina 2022; 6: 58-64
3 Russell S, Bennett J, Wellman JA. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390: 849-860
4 Bainbridge JW, Mehat MS, Sundaram V. et al. Long-term effect of gene therapy on Leberʼs congenital amaurosis. N Engl J Med 2015; 372: 1887-1897
5 Fischer MD, Ochakovski GA, Beier B. et al. Changes in Retinal Sensitivity after Gene Therapy in Choroideremia. Retina 2020; 40: 160-168
6 Michalakis S, Gerhardt M, Rudolph G. et al. Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials. Klin Monbl Augenheilkd 2021; 238: 272-281
7 Guimaraes TAC, Georgiou M, Bainbridge JWB. et al. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br J Ophthalmol 2021; 105: 151-157